How KRAS Mutations Impair Intrinsic GTP Hydrolysis: Experimental and Computational Investigations
Journal of Chemical Information and Modeling · 2025
DOI: 10.1021/acs.jcim.5c02061 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Chemical Information and Modeling, 2025. Verfasst von Lin Frank Song und 9 weiteren Autor:innen. Beteiligte Einrichtung: Physical and Life Sciences Directorate, Lawrence Livermore National Laboratory, Livermore, California 94551, United States. Hauptthemen laut MEDLINE: Guanosine Triphosphate, Proto-Oncogene Proteins p21(ras), Mutation. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 82 Literaturangaben. Gefördert von: National Cancer Institute, Lawrence Livermore National Laboratory.
Abstract (Originalsprache)
Oncogenic KRAS mutations impair GTP hydrolysis and increase the active GTP-bound KRAS population, which leads to growth-factor-independent cell proliferation and survival of cancer cells. Despite notable successes of small-molecule inhibitors in the treatment of KRASG12C cancer, many of these small-molecule inhibitors preferentially bind to inactive (GDP-bound) mutant KRAS, whose availability is limited by the slow rate of intrinsic GTP hydrolysis. A better understanding of how KRAS mutations impair intrinsic hydrolysis is important for designing more effective small-molecule therapeutics. In this work, experimental and computational approaches were utilized to investigate how the most important oncogenic mutations affect the intrinsic hydrolysis of GTP. We found that Q61H, G12V, and G12R mutations impair intrinsic hydrolysis by around 7-fold, 9-fold, and more than 20-fold, respectively, whereas G12A, G12C, G12D, and G13D have less effect. Based on mechanistic investigations, we propose that KRAS mutations impair intrinsic hydrolysis by disrupting the interactions needed to align the nucleophilic water molecule with GTP for nucleophilic attack. These results can assist small-molecule inhibitor design and also benefit the development of other therapeutic strategies, such as rescuing hydrolysis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Physical and Life Sciences Directorate, Lawrence Livermore National Laboratory, Livermore, California 94551, United States.
- NCI RAS Initiative, The Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland 21701, United States.
- Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California 94115, United States.
ORCID-Profile: Semiha K Bali, Andrew G Stephen
Förderung
- National Cancer Institute
- Lawrence Livermore National Laboratory
Zitieren
APA
Song, L. F., Rabara, D., Bali, S. K., Pei, J., Lau, E. Y., Kirshner, D., Lightstone, F. C., McCormick, F., Stephen, A. G., & Yang, Y. (2025). How KRAS Mutations Impair Intrinsic GTP Hydrolysis: Experimental and Computational Investigations. Journal of Chemical Information and Modeling. https://doi.org/10.1021/acs.jcim.5c02061
Vancouver
Song LF, Rabara D, Bali SK, Pei J, Lau EY, Kirshner D, et al. How KRAS Mutations Impair Intrinsic GTP Hydrolysis: Experimental and Computational Investigations. Journal of Chemical Information and Modeling. 2025. doi:10.1021/acs.jcim.5c02061
BibTeX
@article{Song2025,
author = {Song, Lin Frank and Rabara, Dana and Bali, Semiha K and Pei, Jun and Lau, Edmond Y and Kirshner, Dan and Lightstone, Felice C and McCormick, Frank and Stephen, Andrew G and Yang, Yue},
title = {How KRAS Mutations Impair Intrinsic GTP Hydrolysis: Experimental and Computational Investigations},
journal = {Journal of Chemical Information and Modeling},
year = {2025},
doi = {10.1021/acs.jcim.5c02061}
}
EUVIMED